



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,  
Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 22<sup>nd</sup> July, 2022

To  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Sub: Press Release – Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We are enclosing herewith Press Release dated 22<sup>nd</sup> July, 2022 regarding the Company has received CEP approval for Ibuprofen from the European Directorate for the Quality of Medicines & HealthCare (EDQM).

Kindly take the same on record.

Thanking you.

Yours Faithfully

**For SMS Pharmaceuticals Limited**

  
**Thirumalesh Tumma**  
Company Secretary  


Encl: a/a

## Press Release

# **SMS Pharmaceuticals Limited receives Certificate of Suitability (CEP) approval for Ibuprofen by EDQM**

**Hyderabad, July 22, 2022:** SMS Pharmaceuticals Limited has received CEP approval for Ibuprofen from the European Directorate for the Quality of Medicines & HealthCare (EDQM).

**Commenting on this Mr. P. Vamsi Krishna, Executive Director – SMS Pharmaceuticals Limited said,**

*“We are pleased to receive the CEP approval for Ibuprofen by the EDQM. This we believe is a testimony of the company’s quality standards and capabilities. With this, the company can start selling Ibuprofen in the European markets. The company will continue to explore avenues to further grow the revenue from Ibuprofen.*”

*The company’s growth trajectory is expected to accelerate further, in the upcoming quarters underpinned by the recovery in the key products and further geographic expansion for Ibuprofen and other products. The Company is committed to meeting the highest quality standards and is further committed to be fully compliant with the GMP regulations at all our manufacturing facilities.”*

### **About SMS Pharmaceuticals Limited**

Established in 1990, SMS Pharma is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state-of-the-art facilities. The Company has capabilities in wide range of APIs / intermediates and has handled varied process reactions and reactor volumes up to 2,000 KL. The company undertakes contract manufacturing of API, Intermediates (advanced and basic) offering a competitive advantage to its clients especially in late stage lifecycle of products. The Company has demonstrated its manufacturing excellence over the past 2 decades in a broad portfolio of therapeutic segments by being a trusted partner to a customer base in over 70 countries (including clientele in top 20 pharma companies). With 2 manufacturing facilities (two USFDA inspected), 2 pilot plants, 1 R&D center and 1 USFDA approved Independent Testing Laboratory, SMS Pharma is an ideal partner for custom synthesis, process development and mass manufacturing of customer’s own discovery products.

For more information, please visit [smspharma.com](http://smspharma.com)

### **Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information please contact:**



**SMS Pharmaceuticals Limited**

CIN: L24239TG1987PLC008066

Mr. Thirumalesh Tumma

Email: [complianceofficer@smspharma.com](mailto:complianceofficer@smspharma.com)

Contact no.: +91 9100123244

**SGA** Strategic Growth Advisors

**Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar

Email: [jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [chinmay.m@sgapl.net](mailto:chinmay.m@sgapl.net)

Contact no.: +91 9920602034 / +91 9860088296